Core Viewpoint - Exagen Inc. is set to release its financial results for the quarter and year ended December 31, 2024, on March 11, 2025, with a conference call scheduled to discuss the results [1]. Company Overview - Exagen Inc. is a leading provider of autoimmune diagnostics, focused on improving care for patients with chronic autoimmune conditions [4]. - The company's flagship product, AVISE® CTD, aids clinicians in diagnosing complex autoimmune diseases such as lupus, rheumatoid arthritis, and Sjögren's syndrome with greater accuracy [4]. - Exagen specializes in testing for rheumatic diseases, offering a comprehensive suite of AVISE-branded tests for diagnosis, prognosis, and monitoring [4]. - The company emphasizes research, innovation, education, and patient-centered care to tackle challenges in autoimmune disease management [4]. Conference Call Details - The conference call will be hosted by John Aballi, President and CEO, and Jeff Black, CFO, at 8:30 AM ET on March 11, 2025 [1]. - Interested parties can access the call via phone or webcast through the Exagen investor relations website [2]. - A replay of the conference call will be available until April 14, 2025, with specific access details provided [3].
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025